Development of Medical Countermeasures for COVID-19

NIH RePORTER · NIH · N01 · $2,896,627 · view on reporter.nih.gov ↗

Abstract

This contract supports the advanced development of promising therapeutic candidates with broad spectrum activity. The research and development activities to be supported will allow candidate therapeutic products to progress through the product development pipeline, and includes preclinical and non-clinical activities, as well as IND development activities.

Key facts

NIH application ID: 10250293
Project number: 272201300017C-P00023-9999-1
Recipient: BIOCRYST PHARMACEUTICALS, INC.
Principal Investigator: RAYMOND TAYLOR
Activity code: N01
Funding institute: NIH
Fiscal year: 2020
Award amount: $2,896,627
Award type: —
Project period: 2020-08-11 → 2022-09-30